

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A pharmaceutical product for the treatment of viral infections, comprising bleomycin and a virus-inhibiting compound.
2. (Canceled)
3. (Previously Presented) The pharmaceutical product according to claim 1, wherein the virus-inhibiting compound is a protease-inhibitor.
4. (Previously Presented) The pharmaceutical product according to claim 3, wherein the protease-inhibitor is ritonavir.
5. (Previously Presented) The pharmaceutical product according to claim 1, wherein the virus-inhibiting compound is a reverse transcriptase inhibitor.
6. (Previously Presented) The pharmaceutical product according to claim 5, wherein the reverse transcriptase inhibitor is a dideoxyinosine.
7. (Previously Presented) The pharmaceutical product according to claim 1, wherein the viral infection-to be treated is a viral infection with human immunodeficiency virus (HIV).
8. (Previously Presented) A method to treat viral infections in a patient with a viral infection, comprising the steps of:  
administering to the patient a pharmaceutically effective amount of bleomycin; and  
administering to the patient a pharmaceutically effective amount of a virus-inhibiting compound.

9. (Previously Presented) The method of claim 8, wherein the viral infection to be treated is a viral infection with human immunodeficiency virus (HIV).

10. (Previously Presented) The method of claim 8, wherein the virus-inhibiting compound is a protease-inhibitor.

11. (Previously Presented) The method of claim 10, wherein the protease-inhibitor is ritonavir.

12. (Previously Presented) The method of claim 8, wherein the virus-inhibiting compound is a reverse transcriptase inhibitor.

13. (Previously Presented) The method of claim 12, wherein the reverse transcriptase inhibitor is a dideoxyinosine.

14. (Previously Presented) A pharmaceutical product for the treatment of viral infections comprising a hydroxypyridinon and a virus-inhibiting compound.

15. (Previously Presented) The pharmaceutical product of claim 14, wherein the hydroxypyridinon is deferiprone.

16. (Previously Presented) The pharmaceutical product according to claim-14, wherein the virus-inhibiting compound is a protease-inhibitor.

17. (Previously Presented) The pharmaceutical product according to claim 16, wherein the protease-inhibitor is ritonavir.

18. (Previously Presented) The pharmaceutical product according to claim 14, wherein the virus-inhibiting compound is a reverse transcriptase inhibitor.

19. (New) The pharmaceutical product according to claim 18, wherein the reverse transcriptase inhibitor is a dideoxyinosine.

20. ~~19.~~ (Currently Amended) The pharmaceutical product according to claim 14, wherein the viral infection to be treated is a viral infection with human immunodeficiency virus (HIV).

21. ~~20.~~ (Currently Amended) A method to treat viral infections in a patient with a viral infection, comprising the steps of:

administering to the patient a pharmaceutically effective amount of a hydroxypyridinon; and  
administering to the patient a pharmaceutically effective amount of a virus-inhibiting compound.

22. (Currently Amended) ~~21. The method of claim 20~~ The method of claim 21, wherein the viral infection to be treated is a viral infection with human immunodeficiency virus (HIV).

23. (Currently Amended) The method of ~~claim 20~~ claim 21, wherein the hydroxypyridinon is deferiprone.

24. (Currently Amended) The method of ~~claim 20~~ claim 21, wherein the virus-inhibiting compound is a protease-inhibitor.

25. (Previously Presented) The method of claim 24, wherein the protease-inhibitor is ritonavir.

26. (Currently Amended) The method of ~~claim 20~~ claim 21, wherein the virus-inhibiting compound is a reverse transcriptase inhibitor.

27. (Previously Presented) The method of claim 26, wherein the reverse transcriptase inhibitor is a dideoxyinosine.